These results suggest the importance of multi-cytokine evaluation and novel therapeutic approaches for B-CLL patients that is planned to decrease CL1 and augment CL2/CL3 cytokines [95]. This evidence concerns the gene ADGRL3 and B-cell chronic lymphocytic leukemia.